HIV/AIDS - Research and Palliative Care · 2020 · 14 citations · 53 references
MedicinePreventive MedicineBehavioral HealthDementiaHiv PreventionAntiretroviral TherapyCognitive DeclineCognitive ImpairmentDementia Risk FactorsHiv EpidemiologyNeurocognitive DisordersBinary Logistic RegressionHiv-associated Cognitive ImpairmentHiv-associated DementiaNeurocognitive DeclineNeurocognitive DeficitsNeurocognitive ImpairmentNeurocognitive ProfileTargeted Hiv Screening
BACKGROUND: Modern antiretroviral therapy has extended the life expectancies of people living with HIV; however, the prevention and treatment of their associated neurocognitive decline have remained a challenge. Consequently, it is desirable to investigate the prevalence and predictors of neurocognitive impairment to help in targeted screening and disease prevention. MATERIALS AND METHODS: Two hundred and forty-four people living with HIV were interviewed in a study using a cross-sectional design and the International HIV Dementia Scale (IHDS). Additionally, the sociodemographic, clinical, and psychosocial characteristics of the patients were recorded. Chi-square and binary logistic regression analysis were used to determine the level of significance among the independent risk factors and probable neurocognitive impairment. RESULTS: The point prevalence of neurocognitive impairment was found to be 39.3%. Participants' characteristics of being older than 40 years (AOR= 2.81 (95% CI; 1.11-7.15)), having a history of recreational drug use (AOR= 13.67 (95% CI; 6.42-29.13)), and being non-compliant with prescribed medications (AOR= 2.99 (95% CI; 1.01-8.87)) were independent risk factors for neurocognitive impairment. CONCLUSION: The identification of predictors, in the Ethiopian people living with HIV, may help in the targeted screening of vulnerable groups during cART follow-up visits. This may greatly help in strategizing and implementation of the prevention program, more so, because (i) HIV-associated neurocognitive impairment is an asymptomatic condition for considerable durations, and (ii) clinical trials on neurocognitive impairment therapies have been unsuccessful.
53
Updated research nosology for HIV-associated neurocognitive disorders
Andrea Antinori, Gabriele Arendt, James T. Becker et al. · Neurology · 2007 · 2.6K citations
Medicine, Neurology, Neuroscience +14
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy
Robert K. Heaton, David B. Clifford, Donald Franklin et al. · Neurology · 2010 · 2.3K citations · Full text
Medicine, Neurology, Psychiatry +17
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia
Samanta Simioni, Matthias Cavassini, Jean-Marie Annoni et al. · AIDS · 2010 · 702 citations